A Phase 1 interventional study of QRL-101 and Placebo in Healthy Participant Study, sponsored by QurAlis Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by QurAlis Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
QRL-101-08 is a multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a novel formulation of QRL-101 in healthy participants.
Phase 1, single-site, multiple dose study to evaluate the safety, tolerability, and PK of a novel formulation of QRL-101 in healthy participants. Up to 4 cohorts of 12 participants each, randomized 9:3 (QRL-101:placebo) will be tested. The approximate total duration of study participation for each participant may be up to 59 days.
QurAlis Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: QRL-101
Drug: Placebo
Multiple-ascending doses of QRL-101 will be orally administered to healthy participants.
Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
Safety and tolerability
Number of participants with one or more treatment emergent adverse events and serious adverse events. A summary of treatment emergent adverse events (AEs), serious adverse events (SAEs), and other non-serious adverse events, regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101
Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101
Time frame: Time Frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Maximum observed concentration of QRL-101
Maximum observed concentration (Cmax) of QRL-101
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Time of maximum concentration of QRL-101
Time of maximum concentration (Tmax) of QRL-101
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Concentration of QRL-101 before the next dose
Concentration of QRL-101 reached by a drug immediately before the next dose
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Terminal elimination half-life of QRL-101
Terminal elimination half-life of QRL-101
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101 major metabolites
Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101 major metabolites
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Maximum observed concentration of QRL-101 major metabolites
Maximum observed concentration (Cmax) of QRL-101 major metabolites
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Time of maximum concentration of QRL-101 major metabolites
Time of maximum concentration (Tmax) of QRL-101 major metabolites
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Concentration of QRL-101 major metabolites before the next dose
Concentration of QRL-101 major metabolites reached by a drug immediately before the next dose
Time frame: Baseline through Follow up (Day 29)
Pharmacokinetics (plasma): Terminal elimination half-life of QRL-101 major metabolites
Terminal elimination half-life of QRL-101 major metabolites
Time frame: Baseline through Follow up (Day 29)
Ran from Feb 2026 to primary completion in Aug 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QRL-101
QurAlis Corporation